Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
VRTX submitted a Form 144 notice reporting the proposed sale of 40,000 common shares. The filing lists an aggregate dollar amount of $19,738,905.28 and shows 254,034,190 shares on the line that includes 02/27/2026.
The entries list multiple restricted stock vesting dates (02/10/2025, 02/17/2025, 02/24/2025, 02/26/2025) with vesting quantities of 9,681, 6,998, 8,282, and 15,039 shares respectively. The form identifies Fidelity Brokerage Services LLC as the broker on a NASDAQ-listed common security.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., the company’s EVP, COO and CFO, reported a Form 4 transaction involving company common stock. On February 24, 2026, he had 1,744 shares of Vertex common stock disposed of in a transaction coded “F,” which represents payment of tax liability by delivering securities, at a price of $485.11 per share. After this tax-withholding disposition, Wagner directly owned 47,042 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported two transactions in Vertex common stock. She completed an open-market sale of 260 shares at $486.35 per share under a company-approved Rule 10b5-1 trading plan. In a separate transaction, she disposed of 1,627 shares at $485.11 per share to cover tax obligations. After these transactions, she directly holds 46,763 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported share sales and related tax withholding transactions. On February 25, 2026, he completed an open-market sale of 1,846 shares of common stock at $486.35 per share, leaving him with 55,570 directly held shares.
On February 24, 2026, he disposed of 1,518 shares of common stock at $485.11 per share to cover tax obligations by delivering shares. He also reported indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in a trust. The filing notes that the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025.
Vertex Pharmaceuticals executive Duncan McKechnie reported multiple stock transactions. On February 25, 2026, he made open-market sales of 2,500 common shares at $486.35 per share and 2,410 shares at $489.00 per share.
On February 24, 2026, 873 shares were disposed of at $485.11 per share to cover tax obligations by delivering shares. After these transactions, he directly owned 17,559 Vertex common shares. The filing notes the sales were made under a company-approved Rule 10b5-1 trading plan entered on November 25, 2025.
Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported a Form 4 transaction involving a tax-withholding disposition of 3,547 shares of common stock at $485.11 per share on February 24, 2026. After this transaction, he directly owned 34,797 shares and indirectly held 440 shares through a 401(k) plan.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported a tax-related share transaction. On this Form 4, she had 4,981 shares of common stock withheld at $485.11 per share to cover taxes, a type of non-market disposition. After this, she directly owned 138,278 shares of Vertex common stock.
Vertex Pharmaceuticals executive Mark E. Bunnage reported two stock dispositions. On February 25, 2026, he completed an open-market sale of 620 shares of common stock at an average price of $486.35 per share. After this sale, he directly held 7,284 shares.
On February 24, 2026, he disposed of 582 shares at an average price of $485.11 per share to cover tax obligations, rather than as an open-market sale. The transactions were made under a company-approved Rule 10b5-1 trading plan that Dr. Bunnage entered into on November 26, 2025.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported a tax-related share disposition. On February 24, 2026, she transferred 1,453 shares of Vertex common stock at an indicated price of $485.11 per share to cover tax obligations by delivering shares rather than cash. After this tax-withholding transaction, she directly owned 40,063 Vertex common shares.